ZIOPHARM Oncology Inc (ZIOP) EVP David M. Md Mauney Acquires 4,270 Shares of Stock
ZIOPHARM Oncology Inc (NASDAQ:ZIOP) EVP David M. Md Mauney purchased 4,270 shares of the company’s stock in a transaction dated Wednesday, November 8th. The stock was bought at an average price of $4.68 per share, with a total value of $19,983.60. Following the completion of the transaction, the executive vice president now directly owns 58,662 shares of the company’s stock, valued at $274,538.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Shares of ZIOPHARM Oncology Inc (ZIOP) traded down $0.25 during trading on Friday, reaching $4.30. The company had a trading volume of 3,276,056 shares, compared to its average volume of 1,335,313. ZIOPHARM Oncology Inc has a 52 week low of $4.16 and a 52 week high of $7.88.
ZIOPHARM Oncology (NASDAQ:ZIOP) last issued its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.13) earnings per share for the quarter, hitting the consensus estimate of ($0.13). The business had revenue of $1.60 million during the quarter, compared to analysts’ expectations of $1.66 million. The company’s revenue was up .0% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.11) earnings per share. analysts anticipate that ZIOPHARM Oncology Inc will post -0.54 EPS for the current fiscal year.
WARNING: “ZIOPHARM Oncology Inc (ZIOP) EVP David M. Md Mauney Acquires 4,270 Shares of Stock” was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The legal version of this piece can be viewed at https://www.watchlistnews.com/ziopharm-oncology-inc-ziop-evp-david-m-md-mauney-acquires-4270-shares-of-stock/1694241.html.
Institutional investors have recently modified their holdings of the stock. Canada Pension Plan Investment Board purchased a new position in ZIOPHARM Oncology in the second quarter worth approximately $1,010,000. Tudor Investment Corp ET AL grew its position in ZIOPHARM Oncology by 390.4% in the second quarter. Tudor Investment Corp ET AL now owns 63,304 shares of the biotechnology company’s stock worth $394,000 after acquiring an additional 50,395 shares during the period. Swiss National Bank grew its position in ZIOPHARM Oncology by 21.3% in the second quarter. Swiss National Bank now owns 218,920 shares of the biotechnology company’s stock worth $1,362,000 after acquiring an additional 38,500 shares during the period. TIAA CREF Investment Management LLC grew its position in ZIOPHARM Oncology by 6.8% in the second quarter. TIAA CREF Investment Management LLC now owns 350,435 shares of the biotechnology company’s stock worth $2,180,000 after acquiring an additional 22,348 shares during the period. Finally, State of Wisconsin Investment Board purchased a new position in ZIOPHARM Oncology in the second quarter worth approximately $622,000. Institutional investors own 41.86% of the company’s stock.
ZIOP has been the subject of a number of analyst reports. HC Wainwright set a $10.00 price target on ZIOPHARM Oncology and gave the company a “buy” rating in a research report on Tuesday, August 1st. BidaskClub upgraded ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research report on Tuesday, August 8th. ValuEngine upgraded ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research report on Monday, August 28th. Finally, Zacks Investment Research upgraded ZIOPHARM Oncology from a “hold” rating to a “buy” rating and set a $5.25 price objective for the company in a research report on Friday. Two analysts have rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $12.58.
About ZIOPHARM Oncology
ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.
Receive News & Ratings for ZIOPHARM Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.